rosiglitazone has been researched along with thapsigargin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bronfman, M; Fuenzalida, K; Jin, YN; Johnson, GVW; Quintanilla, RA | 1 |
| Hwang, WY; Jin, YN; Jo, C; Johnson, GV | 1 |
2 other study(ies) available for rosiglitazone and thapsigargin
| Article | Year |
|---|---|
Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
Topics: Anilides; Animals; Corpus Striatum; Huntingtin Protein; Huntington Disease; Hypoglycemic Agents; Membrane Potentials; Mice; Mitochondria; Mutation; Nerve Tissue Proteins; Nuclear Proteins; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Thapsigargin; Thiazolidinediones | 2008 |
Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARĪ³.
Topics: Anilides; Animals; Blotting, Western; Cell Line; Cells, Cultured; Glucose; Huntington Disease; Hydrogen Peroxide; Membrane Potential, Mitochondrial; Mice; Polymerase Chain Reaction; PPAR gamma; Pyruvic Acid; Rats; Reactive Oxygen Species; Rolipram; Rosiglitazone; Superoxides; Thapsigargin; Thiazolidinediones | 2012 |